|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:vemurafenib
gptkb:Merck_Serono
|
|
gptkbp:activities
|
BRAF inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Zelboraf
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
gptkb:BRIM-2
gptkb:BRIM-3
Phase III
BRIM-1
|
|
gptkbp:contraindication
|
hypersensitivity to vemurafenib
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zelboraf
|
|
gptkbp:indication
|
gptkb:BRAF_V600_E_mutation-positive_melanoma
|
|
gptkbp:ingredients
|
gptkb:vemurafenib
C23 H22 Cl F2 N3 O2 S
|
|
gptkbp:interacts_with
|
CY P450 inducers
CY P450 inhibitors
|
|
gptkbp:is_atype_of
|
L01 X E30
|
|
gptkbp:is_used_for
|
treatment of melanoma
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:2011
|
|
gptkbp:pharmacokinetics
|
metabolized by liver
bioavailability 100% (oral)
half-life 57 hours
|
|
gptkbp:population
|
adults
|
|
gptkbp:previous_name
|
gptkb:vemurafenib
|
|
gptkbp:price
|
high
|
|
gptkbp:safety_features
|
photosensitivity
skin cancer risk
hepatotoxicity
QT prolongation
ocular toxicity
|
|
gptkbp:side_effect
|
fatigue
nausea
rash
joint pain
itching
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|